• Research Institutes and/or Public Policy Analysis

• 19.

THE ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS INC

The Alliance for the Prudent Use of Antibiotics is the leading global NGO working to improve antibiotic access, policy, and clinical practice worldwide.

• Public Health Programs

• 20.

Committee To Reduce Infection Deaths Inc

RID is dedicated to protecting patients from deadly hospital-acquired infections.

• Other Medical Research N.E.C.

• 21.

Musculoskeletal Infection Study Group Inc

STUDY OP MUSCULOSKELETAL INFECTION AND TREATMENT PROGRAMS.

Peggy Lillis Foundation

Peggy Lillis Foundation is the leading C.

• Biological, Life Science Research (includes Marine Biology, Physiology, Biochemistry, Genetics, Biotechnology, etc.)

• 23.

SMALL WORLD INITIATIVE

Tackling Real-World Health Challenges Through Inspiring and Innovative Science Curriculum The Small World Initiative® (SWI) strives to combine technology, science, and innovation to make meaningful and measurable improvements in the global education and healthcare landscape.

• Other Medical Research N.E.C.

• 24.

Phare Bio Inc

Phare Bio Charting a new era of antibiotics Partnered with the Collins Lab at MIT and the Broad Institute in building the firstever generative AI platform for novel antibiotic discovery.

• Nerve, Muscle, and Bone Research

• 25.

International Consensus Meeting On Infection

International Consensus Meeting on Musculoskeletal Infection THE MISSION OF THE INTERNATIONAL CONSENSUS MEETING ON INFECTION IS TO ORGANIZE, WRITE, AND DISTRIBUTE CONSENSUS STATEMENTS AND OTHER GUIDELINES IN THE FIELD OF ORTHOPAEDICS.

• Digestive Diseases/Disorders Research

• 26.

MICROBIOME HEALTH RESEARCH INSTITUTE INC

OpenBiome is a pioneering nonprofit microbiome health organization, accelerating bold discoveries in microbiome science to improve health for all.

• Promotion of Business (Chambers of Commerce)

• 27.

MICROBIOME THERAPEUTIC INNOVATION GROUP

MTIG is dedicated to enhancing the regulatory, investment, and commercial environment to accelerate microbiome therapeutic drug product development.